Photo from wikipedia
Selexipag is a prostacyclin receptor agonist approved for the treatment of pulmonary arterial hypertension. Cytochrome P450 (CYP) 2C8 is involved in the metabolism of selexipag and its active metabolite, ACT‐333679.… Click to show full abstract
Selexipag is a prostacyclin receptor agonist approved for the treatment of pulmonary arterial hypertension. Cytochrome P450 (CYP) 2C8 is involved in the metabolism of selexipag and its active metabolite, ACT‐333679. This study evaluated the interaction of selexipag and clopidogrel, a CYP2C8 inhibitor.
Keywords:
selexipag;
active metabolite;
cyp2c8 inhibitor;
clopidogrel cyp2c8
Journal Title: British Journal of Clinical Pharmacology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: British Journal of Clinical Pharmacology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!